{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134618","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.208875+00:00","generated_at":"2026-05-15T08:12:41.611849+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"ORIC provides rinzimetostat Phase 1b dose optimization update","bullets":["Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).","No numerical results or conclusions are disclosed in the 8-K filing itself.","Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134618","json":"https://secwatch.observer/filing/0001193125-26-134618.json","markdown":"https://secwatch.observer/filing/0001193125-26-134618.md","text":"https://secwatch.observer/filing/0001193125-26-134618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/0001193125-26-134618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:12:41.611849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}